ホスホジエステラーゼ(PDE)阻害薬の世界市場2019-2023

◆英語タイトル:Global Phosphodiesterase (PDE) inhibitors Market 2019-2023
◆商品コード:IRTNTR31686
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年7月20日
◆ページ数:134
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア、ヨーロッパ、北米、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、ホスホジエステラーゼ(PDE)阻害薬の世界市場について調べ、ホスホジエステラーゼ(PDE)阻害薬の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、ホスホジエステラーゼ(PDE)阻害薬の市場規模をセグメンテーション別(用途別(経口、局所、その他の投与経路)、)と地域別(アジア、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社はホスホジエステラーゼ(PDE)阻害薬の世界市場規模が2019-2023期間中に年平均6%成長すると予測しています。
・サマリー
・レポートの範囲
・ホスホジエステラーゼ(PDE)阻害薬の市場状況
・ホスホジエステラーゼ(PDE)阻害薬の市場規模
・ホスホジエステラーゼ(PDE)阻害薬の市場予測
・ホスホジエステラーゼ(PDE)阻害薬の世界環境:ファイブフォース分析
・市場セグメンテーション:用途別(経口、局所、その他の投与経路)
・ホスホジエステラーゼ(PDE)阻害薬の顧客状況
・主要地域別市場規模:アジア、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Phosphodiesterase (PDE) inhibitors Market: About this market

Phosphodiesterase inhibitors represent a drug class comprising drugs with a similar mechanism of action i.e. by inhibiting PDE enzymes. Technavio’s phosphodiesterase inhibitors market analysis considers sales from oral, topical, and other RoA. Our analysis also considers the sales of phosphodiesterase inhibitors in Asia, Europe, North America, and ROW. In 2018, the oral segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as low cost, and accurate dosage and stability will play a significant role in the oral segment to maintain its market position. Also, our global phosphodiesterase inhibitors market report also looks at factors such as growing adoption of poor lifestyle habits, rising prevalence of erectile dysfunction (ED), and availability of next-generation PDE inhibitors. However, potent drug interactions of PDE inhibitors, side-effects associated with PDE inhibitors, and launch of generics may hamper the growth of the phosphodiesterase inhibitors industry over the forecast period.

Global Phosphodiesterase (PDE) inhibitors Market: Overview

Rising prevalence of erectile dysfunction (ED)

The etiology of ED can be attributed to multiple factors, such as diabetes mellitus, testosterone deficiency, prostate cancer, obesity, hypertension, and hyperlipidemia. In addition, the consumption of certain medicines and substance abuse can lead to ED. As most of these factors are related to lifestyle changes, the prevalence of ED is increasing globally. Rapid urbanization, and the inherent lifestyle changes, along with high stress at the workplace are rendering young men more susceptible to ED. Thus, the increase in the incidence of ED is expected to boost the adoption of PDE inhibitors and drive the market at a CAGR of almost 6% during the forecast period.

Rising burden of chronic diseases

Chronic diseases are among the leading causes of death and contribute to a significant portion of annual healthcare expenditure. Rising healthcare costs associated with chronic diseases such as heart disease, stroke, diabetes and prediabetes is expected to lead to an increase in the adoption of PDE5 inhibitors. Thus, an increase in the economic and health burden of these diseases will ensure continuous or increased use of PDE5 inhibitors for their remission, which will promote market growth during the forecast period.

For the detailed list of factors that will drive the global phosphodiesterase inhibitors market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global phosphodiesterase inhibitors market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading phosphodiesterase inhibitors manufacturers, that include Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., Vivus Inc.

Also, the phosphodiesterase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: PIPELINE LANDSCAPE

PART 07: MARKET SEGMENTATION BY APPLICATION

Market segmentation by application

Comparison by application

Oral – Market size and forecast 2018-2023

Topical – Market size and forecast 2018-2023

Other RoA – Market size and forecast 2018-2023

Market opportunity by application

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 12: MARKET TRENDS

Application of novel technologies for PDE inhibitors development

Growing geriatric population

Rising burden of chronic diseases

PART 13: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 14: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Bayer AG

Eli Lilly and Co.

GlaxoSmithKline Plc

Pfizer Inc.

Vivus Inc.

PART 15: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

Exhibit 1: Global pharmaceuticals market

Exhibit 2: Segments of global pharmaceuticals market

Exhibit 3: Market characteristics

Exhibit 4: Market segments

Exhibit 5: Some of the commercially available PDE inhibitors

Exhibit 6: Disease targets for different PDE inhibitors

Exhibit 7: Market definition – Inclusions and exclusions checklist

Exhibit 8: Market size 2018

Exhibit 9: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 11: Five forces analysis 2018

Exhibit 12: Five forces analysis 2023

Exhibit 13: Bargaining power of buyers

Exhibit 14: Bargaining power of suppliers

Exhibit 15: Threat of new entrants

Exhibit 16: Threat of substitutes

Exhibit 17: Threat of rivalry

Exhibit 18: Market condition – Five forces 2018

Exhibit 19: Some of the phase III clinical trials of PDE inhibitors

Exhibit 20: Application – Market share 2018-2023 (%)

Exhibit 21: Comparison by application

Exhibit 22: Oral – Market size and forecast 2018-2023 ($ millions)

Exhibit 23: Advantages of tablet dosage form

Exhibit 24: Oral – Year-over-year growth 2019-2023 (%)

Exhibit 25: Topical – Market size and forecast 2018-2023 ($ millions)

Exhibit 26: Topical – Year-over-year growth 2019-2023 (%)

Exhibit 27: Other RoA – Market size and forecast 2018-2023 ($ millions)

Exhibit 28: Other RoA – Year-over-year growth 2019-2023 (%)

Exhibit 29: Market opportunity by application

Exhibit 30: Customer landscape

Exhibit 31: Market share by geography 2018-2023 (%)

Exhibit 32: Geographic comparison

Exhibit 33: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: North America – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in North America

Exhibit 36: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 38: Top 3 countries in Europe

Exhibit 39: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 40: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 41: Top 3 countries in Asia

Exhibit 42: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 43: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 44: Top 3 countries in ROW

Exhibit 45: Key leading countries

Exhibit 46: Market opportunity

Exhibit 47: Role of PDE5 inhibitors in ED

Exhibit 48: Sales of PDE5 inhibitors after the launch of generics ($ millions)

Exhibit 49: Impact of drivers and challenges

Exhibit 50: CDC statistics about chronic diseases in geriatric population in the US over the past few years

Exhibit 51: Geriatric population scenario in the US

Exhibit 52: Vendor landscape

Exhibit 53: Landscape disruption

Exhibit 54: Vendors covered

Exhibit 55: Vendor classification

Exhibit 56: Market positioning of vendors

Exhibit 57: Bayer AG – Vendor overview

Exhibit 58: Bayer AG – Product segments

Exhibit 59: Bayer AG – Organizational developments

Exhibit 60: Bayer AG – Geographic focus

Exhibit 61: Bayer AG – Segment focus

Exhibit 62: Bayer AG – Key offerings

Exhibit 63: Bayer AG – Key customers

Exhibit 64: Eli Lilly and Co. – Vendor overview

Exhibit 65: Eli Lilly and Co. – Business segments

Exhibit 66: Eli Lilly and Co. – Organizational developments

Exhibit 67: Eli Lilly and Co. – Geographic focus

Exhibit 68: Eli Lilly and Co. – Segment focus

Exhibit 69: Eli Lilly and Co. – Key offerings

Exhibit 70: Eli Lilly and Co. – Key customers

Exhibit 71: GlaxoSmithKline Plc – Vendor overview

Exhibit 72: GlaxoSmithKline Plc – Business segments

Exhibit 73: GlaxoSmithKline Plc – Organizational developments

Exhibit 74: GlaxoSmithKline Plc – Geographic focus

Exhibit 75: GlaxoSmithKline Plc – Segment focus

Exhibit 76: GlaxoSmithKline Plc – Key offerings

Exhibit 77: GlaxoSmithKline Plc – Key customers

Exhibit 78: Pfizer Inc. – Vendor overview

Exhibit 79: Pfizer Inc. – Business segments

Exhibit 80: Pfizer Inc. – Organizational developments

Exhibit 81: Pfizer Inc. – Geographic focus

Exhibit 82: Pfizer Inc. – Segment focus

Exhibit 83: Pfizer Inc. – Key offerings

Exhibit 84: Pfizer Inc. – Key customers

Exhibit 85: Vivus Inc. – Vendor overview

Exhibit 86: Vivus Inc. – Business segments

Exhibit 87: Vivus Inc. – Organizational developments

Exhibit 88: Vivus Inc. – Geographic focus

Exhibit 89: Vivus Inc. – Key offerings

Exhibit 90: Vivus Inc. – Key customers

Exhibit 91: Validation techniques employed for market sizing

Exhibit 92: Definition of market positioning of vendors



【掲載企業】

Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., and Vivus Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ホスホジエステラーゼ(PDE)阻害薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆